Tiziana Life Sciences is a clinical-stage biopharmaceutical enterprise specializing in the discovery and development of breakthrough immunomodulation therapies. The company focuses primarily on utilizing novel alternative routes of drug delivery—such as its proprietary intranasal administration platform—to target complex neurodegenerative and neuroinflammatory disorders. Its core developmental pipeline includes innovative biologic candidates designed to treat conditions like secondary progressive multiple sclerosis, Alzheimer's disease, and amyotrophic lateral sclerosis by dampening localized inflammation without causing broad systemic toxicities.